Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

Leukemia

Volumn 26, Issue 10, 2012, Pages 2186-2196

  Anguille, S ^a,b   Van Tendeloo, V F ^a,b   Berneman, Z N ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Acute myeloid leukemia; Immunotherapy; Leukemia associated antigens; Leukemic stem cells

Indexed keywords

AZACITIDINE; LEUKEMIA ANTIGEN; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CELL DIFFERENTIATION; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; LEUKEMOGENESIS; PASSIVE IMMUNIZATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; LEUKEMIA, MYELOID, ACUTE;

EID: 84867400336     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.145     Document Type: Review

References (132)

1. Anguille S, Lion E, Smits E, Berneman ZN, Van Tendeloo VFI. Dendritic cell vaccine therapy for acute myeloid leukemia Questions and Answers. Hum Vaccines 2011; 7: 579-584.
2. Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL. Interferon-alpha in acute myeloid leukemia: an old drug revisited. Leukemia 2011; 25: 739-748.
3. Smits E, Berneman ZN, Van Tendeloo VFI. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist 2009; 14: 240-252.
4. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-5337.
5. Dasgupta B, Pinilla-Ibarz J, Roberts W, Moldenhauer A, Schwartz J, Rodriguez E et al. Generation of specific T cell immune responses to AML1/ETO in t(8;21) acute myeloid leukemia. Blood 2001; 98: 722A. (Pubitemid 33790271)
6. Makita M, Azuma T, Hamaguchi H, Niiya H, Kojima K, Fujita S et al. Leukemiaassociated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4(+) T lymphocytes. Leukemia 2002; 16: 2400-2407. (Pubitemid 36054374)
7. Osman Y, Takahashi M, Zheng Z, Toba K, Liu A, Furukawa T et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J Exp Clin Cancer Res 1999; 18: 485-492. (Pubitemid 30114737)
8. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369-1375. (Pubitemid 23067377)
9. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
10. Scholl S, Salzmann S, Kaufmann AM, Hoffken K. Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches. Leuk Lymphoma 2006; 47: 307-312. (Pubitemid 43084571)
11. Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM et al. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood 2007; 109: 2985-2988. (Pubitemid 46482098)
12. Greiner J, Ono Y, Hofmann S, Schmitt A, Mehring E, Gotz M et al. Mutated regions of nucleophosmin 1 (NPM1) elicit both CD4+ and CD8+ T cell responses in patients with acute myeloid leukemia. Blood 2012; e-pub ahead of print 16 May 2012; doi: 10.1182/blood-2011-11-394395.
13. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24: e20-e22.
14. Van Driessche A, Berneman ZN, Van Tendeloo VF. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 2012; 17: 250-259.
15. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868-876. (Pubitemid 46672061)
16. Sugiyama H. WT1 (Wilms' Tumor Gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 2010; 40: 377-387.
17. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 2001; 97: 2903-2907.
18. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571-576. (Pubitemid 36841977)
19. Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest 2010; 120: 3869-3877.
20. Snauwaert S, Vanhee S, Goetgeluk G, Verstichel G, Van Caeneghem Y, Velghe I et al. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica 2012; e-pub ahead of print 24 April 2012; doi: 10.3324/haematol.2012.065581.
21. Siegel S, Wagner A, Kabelitz D, Marget M, Coggin Jr J, Barsoum A et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 2003; 102: 4416-4423. (Pubitemid 37494105)
22. Siegel S, Wagner A, Friedrichs B, Wendeler A, Wendel L, Kabelitz D et al. Identification of HLA-A 0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J Immunol 2006; 176: 6935-6944. (Pubitemid 43787874)
23. Maeda M, Otsuka T, Kimura N, Kozu T, Fukuyama T, Uchida N et al. Induction of MTG8-specific cytotoxic T-cell lines: MTG8 is probably a tumour antigen that is recognized by cytotoxic T cells in AML1-MTG8-fused gene-positive acute myelogenous leukaemia. Br J Haematol 2000; 111: 570-579.
24. Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S et al. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005; 335: 1293-1304. (Pubitemid 41215557)
25. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-4117. (Pubitemid 44913282)
26. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004; 108: 704-711. (Pubitemid 38076402)
27. Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MG et al. PRAME specific allo-HLA restricted T-cells with potent antitumor reactivity useful for therapeutic T cell receptor gene transfer. Clin Cancer Res 2011; 17: 5615-5625.
28. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S et al. Identification of therapeutic targets for quiescent, chemotherapy- resistant human leukemia stem cells. Sci Transl Med 2010; 2: 17-19.
29. Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci USA 2009; 106: 3396-3401.
30. Gerber JM, Qin L, Kowalski J, Smith BD, Griffin CA, Vala MS et al. Characterization of chronic myeloid leukemia stem cells. Am J Hematol 2011; 86: 31-37.
31. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006; 20: 2147-2154. (Pubitemid 44782840)
32. Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009; 113: 66-74.
33. Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood 2012; 119: 5492-5501.
34. Stroopinsky D, Rosenblatt J, Ito K, Yin L, Rajabi H, Vasir B et al. Targeting acute myeloid leukemia stem cells by MUC1-C subunit inhibition. Blood 2010; 116: 369-369.
35. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-2203. (Pubitemid 30167714)
36. Greiner J, Bullinger L, Guinn BA, Dohner H, Schmitt M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res 2008; 14: 7161-7166.
37. Schmidt SM, Konig T, Bringmann A, Held S, von Schwarzenberg K, Heine A et al. Characterization of BAX inhibitor-1as a novel leukemia-associated antigen. Leukemia 2009; 23: 1818-1824.
38. Rizo A, Olthof S, Han L, Vellenga E, de Haan G, Schuringa JJ. Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood 2009; 114: 1498-1505.
39. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91: 991-1000. (Pubitemid 28078303)
40. Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T et al. Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 2006; 25: 4217-4229. (Pubitemid 44079455)
41. Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D et al. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia 2002; 16: 846-854. (Pubitemid 34537557)
42. Simpson LA, Burwell EA, Thompson KA, Shahnaz S, Chen AR, Loeb DM. The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood 2006; 107: 4695-4702. (Pubitemid 43882617)
43. Witko-Sarsat V, Canteloup S, Durant S, Desdouets C, Chabernaud R, Lemarchand P et al. Cleavage of p21waf1 by proteinase-3, a myeloid-specific serine protease, potentiates cell proliferation. J Biol Chem 2002; 277: 47338-47347. (Pubitemid 36159248)
44. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest 2004; 113: 175-179. (Pubitemid 38544200)
45. Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM et al. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol 2007; 79: 210-225. (Pubitemid 47231163)
46. Wadia PP, Coram M, Armstrong RJ, Mindrinos M, Butte AJ, Miklos DB. Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. Blood 2010; 115: 2077-2087.
47. Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F et al. RHAMMR3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008; 111: 1357-1365. (Pubitemid 351213422)
48. Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009; 114: 3299-3308.
49. Yin L, Wu Z, Avigan D, Rosenblatt J, Stone R, Kharbanda S et al. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood 2011; 117: 4863-4870.
50. Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 2006; 107: 3303-3312.
51. Schessl C, Rawat VPS, Cusan M, Deshpande A, Kohl TM, Rosten PM et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115: 2159-2168. (Pubitemid 41134157)
52. Oancea C, Ruster B, Henschler R, Puccetti E, Ruthardt M. The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation. Leukemia 2010; 24: 1910-1919.
53. Falini B, Gionfriddo I, Cecchetti F, Ballanti S, Pettirossi V, Martelli MP. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy? Blood Rev 2011; 25: 247-254.
54. Wojiski S, Guibal FC, Kindler T, Lee BH, Jesneck JL, Fabian A et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia 2009; 23: 1462-1471.
55. Kozu T, Komori A, Sueoka E, Fujiki H, Kaneko Y, Matsui T et al. Significance of MTG8 in leukemogenesis. Leukemia 1997; 11(Suppl 3): 297-298.
56. Warner JK, Wang JC, Takenaka K, Doulatov S, McKenzie JL, Harrington L et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 2005; 19: 1794-1805. (Pubitemid 41486158)
57. Lawrence HJ, Rozenfeld S, Cruz C, Matsukuma K, Kwong A, Komuves L et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 1999; 13: 1993-1999.
58. Nolte F, Hofmann W-K. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Fut Oncol 2010; 6: 445-455.
59. Yuan J, Takeuchi M, Negishi M, Oguro H, Ichikawa H, Iwama A. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia 2011; 25: 1335-1343.
60. Brossart P, Schneider A, Dill P, Schammann T, Grunebach F, Wirths S et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001; 61: 6846-6850. (Pubitemid 32896509)
61. Kapp M, Stevanovic S, Fick K, Tan SM, Loeffler J, Opitz A et al. CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant 2009; 43: 399-410.
62. Beatty GL, Smith JS, Reshef R, Patel KP, Colligon TA, Vance BA et al. Functional unresponsiveness and replicative senescence of myeloid leukemia antigenspecific CD8(+) T cells after allogeneic stem cell transplantation. Clin Cancer Res 2009; 15: 4944-4953.
63. Siegel S, Steinmann J, Schmitz N, Stuhlmann R, Dreger P, Zeis M. Identification of a survivin-derived peptide that induces HLA-A 0201-restricted antileukemia cytotoxic T lymphocytes. Leukemia 2004; 18: 2046-2047. (Pubitemid 40028435)
64. Rezvani K, Yong ASM, Tawab A, Jafarpour B, Eniafe R, Mielke S et al. Ex vivo characterization of polyclonal memory CD8(+) T-cell responses to PRAMEspecific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009; 113: 2245-2255.
65. Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H et al. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope. Microbiol Immunol 2008; 52: 551-558.
66. Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002; 100: 3835-3837. (Pubitemid 35303962)
67. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286-293. (Pubitemid 30017254)
68. Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Shortterm cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 2009; 7: 109.
69. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116: 171-179.
70. Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood 2005; 106: 1415-1418. (Pubitemid 41129609)
71. Lehe C, Ghebeh H, Al-Sulaiman A, Al Qudaihi G, Al-Hussein K, Almohareb F et al. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res 2008; 68: 6350-6359.
72. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107: 13824-13829.
73. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemiaassociated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-242.
74. Qazilbash MH, Wieder E, Rios R, Lu SJ, Kant S, Giralt S et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood 2004; 104: 77A.
75. DiPersio JF, Collins RH, Blum W, Devetten MP, Stiff P, Elias L et al. Immune responses in AML patients following vaccination with GRNVAC1, autologous RNA transfected dendritic cells expressing telomerase catalytic subunit hTERT. Blood 2009; 114: 262.
76. Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K et al. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Exp Hematol 2011; 39: 424-433.
77. Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol 2006; 28: 855-861.
78. Molldrem J, Barrett JA. inventors Anti-cancer vaccines (patent application 20060045883) USA 2006.
79. McLarnon A, Piper KP, Goodyear OC, Arrazi JM, Mahendra P, Cook M et al. CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. Haematologica 2010; 95: 1572-1578.
80. Yang XF, Wu CJ, Chen L, Alyea EP, Canning C, Kantoff P et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 2002; 62: 5517-5522.
81. Yang XF, Wu CJ, McLaughlin S, Chillemi A, Wang KS, Canning C et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA 2001; 98: 7492-7497. (Pubitemid 32567976)
82. Zhang W, Choi J, Zeng W, Rogers SA, Alyea EP, Rheinwald JG et al. Graftversus- leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res 2010; 16: 2729-2739.
83. Yong AS, Stephens N, Weber G, Li Y, Savani BN, Eniafe R et al. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia 2011; 25: 629-637.
84. Spierings E, Goulmy E. Expanding the immunotherapeutic potential of minor histocompatibility antigens. J Clin Invest 2005; 115: 3397-3400. (Pubitemid 43121825)
85. Norde WJ, Overes IM, Maas F, Fredrix H, Vos JC, Kester MG et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood 2009; 113: 2312-2323.
86. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Dohner H et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 2003; 106: 224-231. (Pubitemid 36835175)
87. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132-2137. (Pubitemid 35001248)
88. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK et al. T-cell responses directed against multiple HLA-A 0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 2005; 11: 8799-8807. (Pubitemid 43005931)
89. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-1918.
90. Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S et al. Immunogenicity of Bcl-2 in patients with cancer. Blood 2005; 105: 728-734. (Pubitemid 40070759)
91. Suemori K, Fujiwara H, Ochi T, Azuma T, Yamanouchi J, Narumi H et al. Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen- A 2402-restricted cytotoxic T lymphocytes. Cancer Sci 2008; 99: 1414-1419. (Pubitemid 351761732)
92. Suemori K, Fujiwara H, Ochi T, Azuma T, Yamanouchi J, Narumi H et al. Identification of a novel epitope derived from CML66 that is recognized by anti-leukaemia cytotoxic T lymphocytes. Br J Haematol 2009; 146: 115-118.
93. Siegel S, Wirth S, Kabelitz D, Schmitz N, Zeis M. Identification of HLA-A0201- presented T-cell epitopes derived from the tumor-associated antigen M-phase phosphoprotein II in patients with acute myeloid leukemia. Leukemia 2010; 24: 1660-1662.
94. Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios RL, Lu S et al. PR1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival. Blood 2007; 110: 178A.
95. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Goetz M, Funk I et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010; 95: 1191-1197.
96. Khoury HJ, Collins RH, Blum W, Maness L, Stiff P, Kelsey SM et al. Prolonged administration of the telomerase vaccine GRNVAC1 is well tolerated and appears to be associated with favorable outcomes in high-risk acute myeloid leukemia (AML). Blood 2010; 116: 904.
97. Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Gostick E, Ladell K, Roederer M et al. High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood 2009; 113: 2238-2244.
98. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97: 7521-7526. (Pubitemid 30431496)
99. Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell. Leukemia 2004; 18: 1169-1175. (Pubitemid 39023127)
100. Dermime S, Bertazzoli C, Marchesi E, Ravagnani F, Blaser K, Corneo GM et al. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res 1996; 2: 593-600. (Pubitemid 26099179)
101. Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005; 106: 673-680. (Pubitemid 40981265)
102. Walsby E, Walsh V, Pepper C, Burnett A, Milis K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008; 93: 662-669. (Pubitemid 351669305)
103. Sawa M, Yamamoto K, Yokozawa T, Kiyoi H, Hishida A, Kajiguchi T et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 2005; 82: 42-47. (Pubitemid 41512198)
104. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A. Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 2007; 21: 1116-1122. (Pubitemid 46672096)
105. Smith LL, Yeung J, Zeisig BB, Popov N, Huijbers I, Barnes J et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 2011; 8: 649-662.
106. Fujii N, Turtle CJ, Campregher PV, Warren III EH. Generation of CD8(+) cytotoxic T cell clones recognizing BMI1-derived peptides. Blood 2008; 112: 1000-1001.
107. Xie LH, Sin FW, Cheng SC, Cheung YK, Chan KT, Xie Y et al. Activation of cytotoxic T lymphocytes against CML28-bearing tumors by dendritic cells transduced with a recombinant adeno-associated virus encoding the CML28 gene. Cancer Immunol Immunother 2008; 57: 1029-1038.
108. Wu CJ, Biernacki M, Kutok JL, Rogers S, Chen L, Yang XF et al. Graftversus- leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res 2005; 11: 4504-4511. (Pubitemid 40825641)
109. Iida H, Towatari M, Tanimoto M, Morishita Y, Kodera Y, Saito H. Overexpression of cyclin E in acute myelogenous leukemia. Blood 1997; 90: 3707-3713. (Pubitemid 27473442)
110. Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS et al. The shared tumor-associated antigen cytochrome P4501B1 is recognized by specific cytotoxic T cells. Blood 2003; 102: 3287-3294. (Pubitemid 37314768)
111. Kozu T, Komori A, Ishii M. AML1/MTG8, fused gene of t(8;21) AML and clinical usefulness of MTG8 protein and circulating MTG8-autoantibody. Biotherapy 1997; 11: 44-50. (Pubitemid 27123848)
112. Capraro V, Zane L, Poncet D, Perol D, Galia P, Preudhomme C et al. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp Hematol 2011; 39: 195-202.
113. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G et al. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 2003; 9: 4743-4755. (Pubitemid 37323277)
114. Sorensen RB, Nielsen OJ, Thor Straten P, Andersen MH. Functional capacity of Mcl-1-specific cytotoxic T-cells. Leukemia 2006; 20: 1457-1458. (Pubitemid 44084067)
115. Andersen RS, Wenandy L, Sorensen RB, thor Straten P, Andersen MH. Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope. Leukemia 2008; 22: 668-669. (Pubitemid 351386748)
116. Steinbach D, Onda M, Voigt A, Dawczynski K, Wittig S, Hassan R et al. Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. Eur J Haematol 2007; 79: 281-286. (Pubitemid 47390138)
117. de Rijke B, van Horssen-Zoetbrood A, Beekman JM, Otterud B, Maas F, Woestenenk R et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 2005; 115: 3506-3516. (Pubitemid 43121838)
118. Overes IM, Fredrix H, Kester MG, Falkenburg JH, van der Voort R, de Witte TM et al. Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells. J Immunother 2009; 32: 539-551.
119. Dengler R, Munstermann U, al-Batran S, Hausner I, Faderl S, Nerl C et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 1995; 89: 250-257.
120. Braunschweig I, Wang CQ, Molldrem JJ. Cytotoxic T lymphocytes (CTL) specific for myeloperoxidase-derived HLA-A2-restricted peptides specifically lyse AML and CML cells. Blood 2000; 96: 761A.
121. Siegel S, Wirth S, Schweizer M, Schmitz N, Zeis M. M-phase phosphoprotein 11 is a highly immunogenic tumor antigen in patients with acute myeloid leukemia. Acta Haematol 2012; 127: 193-197.
122. Al Qudaihi G, Lehe C, Dickinson A, Eltayeb K, Rasheed W, Chaudhri N et al. Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes. Hematol Oncol Stem Cell Ther 2010; 3: 24-33.
123. Boss CN, Grunebach F, Brauer K, Hantschel M, Mirakaj V, Weinschenk T et al. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res 2007; 13: 3347-3355. (Pubitemid 46944922)
124. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krahn G et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002; 30: 1029-1035. (Pubitemid 35286619)
125. Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P et al. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2- positive patients with acute myeloid leukemia. Blood 2005; 106: 938-945. (Pubitemid 41076438)
126. Guinn B, Greiner J, Schmitt M, Mills KI. Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. Blood 2009; 113: 1203-1204.
127. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111: 196-203.
128. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217-1225. (Pubitemid 27314159)
129. Asemissen AM, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S et al. Identification of a highly immunogenic HLA-A01-binding T cell epitope of WT1. Clin Cancer Res 2006; 12: 7476-7482. (Pubitemid 46095423)
130. Martinez A, Olarte I, Mergold MA, Gutierrez M, Rozen E, Collazo J et al. mRNA expression of MAGE-A3 gene in leukemia cells. Leuk Res 2007; 31: 33-37. (Pubitemid 44709750)
131. Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y et al. Cancertestis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol 2011; 86: 918-922.
132. Guinn BA, Gilkes AF, Mufti GJ, Burnett AK, Mills KI. The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia. Br J Haematol 2006; 134: